Sulofenur

Sulofenur (Diarylsulfonylurea; LY186641) is an orally active anti-tumor agent. Sulofenur induces gene expression through calcium ion-dependent pathways and some protein kinase-independent pathways, and its effect is particularly enhanced in H-ras mutant cells. Sulofenur exhibits significant activity in mouse solid tumor models and human tumor xenograft models[1][2][3].

Product Specifications

CAS Number

[110311-27-8]

Product Name Alternative

Diarylsulfonylurea; LY186641

UNSPSC

12352005

Target

Calcium Channel

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=S(C1=CC2=C(CCC2)C=C1)(NC(NC3=CC=C(Cl)C=C3)=O)=O

Molecular Formula

C16H15ClN2O3S

Molecular Weight

350.82

References & Citations

[1]Gu H, et al. H-ras transfection of the rat kidney cell line NRK-52E results in increased induction of c-fos, c-jun and hsp70 following sulofenur treatment. Cancer Lett. 1996 Sep 10;106 (2) :199-205.|[2]Brown TD, et al. Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule. Anticancer Drugs. 1994 Apr;5 (2) :151-9.|[3]Ehlhardt WJ, et al. Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs. J Pharm Sci. 1993 Jul;82 (7) :683-8.